Novartis announces new leader of Pharmaceuticals Business Unit

NEXT STORY
NeRRe Therapeutics announces positive findings from Phase 2b study with orvepitant in chronic cough
PREV STORY
Oxurion NV – Data from a Phase 1/2 Clinical Study evaluating THR-317 (anti-PlGF) for DME presented at 2019 FLORetina Meeting
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Novartis presents new Cosentyx data showing long-lasting efficacy in psoriatic arthritis over 3 years including patient-reported pain

Cosentyx® data show sustained improvements in the signs and symptoms of psoriatic arthritis (PsA) ...

author_avatar
NASDAQ Market News

RedHill Biopharma Elaborates on Its Announced Positive Top-Line Results from Phase III Study of RHB-104 in Crohn’s Disease

TEL-AVIV, Israel and RALEIGH, N.C., Aug. 01, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. ...

author_avatar
NASDAQ Market News

Resverlogix Announces Topline Results in BETonMACE Phase 3 Epigenetics Trial

author_avatar
NASDAQ Market News